Jonathan Aschoff
Stock Analyst at Roth Capital
(0.53)
# 4,198
Out of 5,138 analysts
38
Total ratings
26.53%
Success rate
-34.88%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Buy | $57 | $25.10 | +127.09% | 1 | Nov 25, 2025 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.66 | +1,566.67% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $9.17 | +129.01% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $199,800 → $106,560 | $9.01 | +1,183,242.59% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.18 | +1,425.42% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $1.90 | +37,478.95% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $500 | $2.86 | +17,382.52% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $4.14 | +24,054.59% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $3.75 | +22,329.91% | 4 | Mar 28, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $3.49 | +515,659.31% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $18.27 | +64.20% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $5.12 | +3,806.25% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $4.96 | +182.26% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $0.90 | +2,399,900.00% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.88 | +325.53% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.85 | +5,305.41% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.81 | +49,294.91% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $9.14 | +315.75% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.64 | +5,753.66% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.54 | +744.16% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Nov 25, 2025
Initiates: Buy
Price Target: $57
Current: $25.10
Upside: +127.09%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.66
Upside: +1,566.67%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.17
Upside: +129.01%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $199,800 → $106,560
Current: $9.01
Upside: +1,183,242.59%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.18
Upside: +1,425.42%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $1.90
Upside: +37,478.95%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $500
Current: $2.86
Upside: +17,382.52%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $4.14
Upside: +24,054.59%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $3.75
Upside: +22,329.91%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $3.49
Upside: +515,659.31%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $18.27
Upside: +64.20%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $5.12
Upside: +3,806.25%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $4.96
Upside: +182.26%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $0.90
Upside: +2,399,900.00%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.88
Upside: +325.53%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $1.85
Upside: +5,305.41%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.81
Upside: +49,294.91%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $9.14
Upside: +315.75%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.64
Upside: +5,753.66%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.54
Upside: +744.16%